feedback regulation of PPP1CA transactivation. Left, Effects of tamoxifen on PPP1CA expression. For immunoblot analysis (upper), b-actin served as a loading control. For real-time PCR analysis (lower), the data are expressed as the fold-increase over untreated cells (set at 1.0). These data represent the mean ± s.e.m. of three independent experiments. Right, ChIP assays of the transactivation of PPP1CA through an ERE motif in 5' upstream (upper) , and luciferase assays of the transactivation of PPP1CA using a luciferase reporter containing an ERE motif conserved within 5' upstream of the PPP1CA gene (lower). The data represent the mean ± s.e.m. of three independent experiments. (g) The predicted PKA binding regions in BIG3, as determined using Hou et al. 24 FLAG-tagged BIG3 (WT, DPP1Ca) and HA-tagged ERa-transfected HEK293T cells, followed by immunoprecipitation with an anti-PHB2 antibody. (c) The inhibitory effect of BIG3-PP1Ca binding inhibitor on PP1Ca phosphatase activity. MCF-7 cells were treated with BIG3-PP1Ca binding inhibitor for 24 h in the presence of E2 and were immunoprecipitated using BIG3 antibody. (d) The effects of PKA inhibitor H-89 and PP1Ca inhibitor okadaic acid on BIG3 phosphorylation (S305 and S1208) and PHB2 phosphorylation (S39). MCF-7 cells were treated with H-89 or okadaic acid for 24 h in the presence of E2 and were immunoprecipitated using BIG3 or PHB2 antibody. (e) Q-TOF spectra indicating dephosphorylation of phospho-PHB2-peptide by PP1Ca in positive ion mode. The dephosphorylation of peptide is exemplarily shown for m/z 643.3. Upper, the left spectrum is an untreated control, and the right spectrum was acquired after dephosphorylation with PP1Ca. Lower, product ion spectrum of the PHB2 peptide YGVRESVFTVE, with a precursor mass of m/z 643.3. *** P<0.001 (two-sided Student's t-test). 
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